Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.54 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.54 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33708 | 0.89 | ADORA3 (1.00) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| SCHEMBL30119602 | 0.89 | ADORA3 (1.00) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| Zygosporin D SCHEMBL34014 | 0.87 | NR0B1 (0.80) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| SCHEMBL29408780 | 0.85 | ADORA3 (0.60) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| SCHEMBL33816 | 0.85 | ADORA3 (0.60) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| SCHEMBL33787 | 0.85 | ADORA3 (0.60) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| SCHEMBL29745674 | 0.83 | ADORA3 (0.59) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| SCHEMBL33793 | 0.83 | ADORA3 (0.59) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| SCHEMBL33544 | 0.80 | ADORA3 (0.56) | ADORA3NR0B1NPC1LMNASLC2A1 | |
| SCHEMBL31734123 | 0.79 | NR0B1 (0.78) | ADORA3NR0B1NPC1LMNASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2919795-B1 | SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES | UNIV CALIFORNIA (US) | 2021-06-30 | — | — | EP | claimed |
| US-9920320-B2 | Methods of modulating compliance of the trabecular meshwork | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-20 | — | — | US | claimed |
| US-20160215285-A1 | METHODS OF MODULATING COMPLIANCE OF THE TRABECULAR MESHWORK | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-28 | — | — | US | claimed |
| US-9206423-B2 | Methods of modulating compliance of the trabecular meshwork | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | claimed |
| EP-2919795-A1 | SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES | The Regents of The University of California (US) | 2015-09-23 | — | — | EP | claimed |
| US-20140187607-A1 | METHODS OF MODULATING COMPLIANCE OF THE TRABECULAR MESHWORK | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-03 | — | — | US | claimed |
| WO-2014077934-A1 | SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-22 | — | — | WO | claimed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | claimed |
| US-20090062904-A1 | STENT COATING | ICON INTERVENTIONAL SYSTEMS, INC. | 2009-03-05 | — | — | US | claimed |
| WO-2008156654-A2 | CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-12-24 | — | — | WO | claimed |
| US-5994388-A | Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1999-11-30 | — | — | US | claimed |
| WO-1998041205-A1 | CYTOCHALASIN AND ISOINDOLINONE DERIVATIVES AS INHIBITORS OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-09-24 | — | — | WO | claimed |
| CN-121872983-A | Preparation method of lactam alkaloid from Acacia farnesiana and application of lactam alkaloid in preparation of antitumor drugs | 华南农业大学 | 2026-04-17 | — | — | CN | disclosed |
| US-20260070124-A1 | METHOD FOR FORMING A TUBE | MIRUS LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12569595-B2 | Bioprosthetic tissue preparation | EDWARDS LIFESCIENCES CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4404878-A1 | COATING FOR REFRACTORY METAL ALLOY | MiRus LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-1994026291-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994016706-A1 | THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070124-A1 | METHOD FOR FORMING A TUBE | NIT2, NFE2L2, DUOX2 | ADORA3 3123/4885NR0B1 2547/4885NPC1 2580/4885 |
| US-12569595-B2 | Bioprosthetic tissue preparation | BCHE, LNPEP, DPEP1 | ADORA3 2883/4885NR0B1 3919/4885NPC1 2049/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | ADORA3 2528/4885NR0B1 3104/4885NPC1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.